🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Mark E. Gurney

California Institute of Technology

ORCID: 0000-0003-4901-3083
Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 1%percentile
6.7Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

COVID‐19 and dementia: Analyses of risk, disparity, and outcomes from electronic health records in the US

Alzheimer s & Dementia(2021)10.1002/alz.12296
Top 3%
6.7DataRank
Top 3%274 citations

Pamela B. Davis, Mark E. Gurney, Rong Xu, QuanQiu Wang

Papers

Driven by 8 papers — median percentile 97. Top paper: “COVID‐19 and dementia: Analyses of risk, disparity, and outcomes from electronic health records in the US”.

COVID‐19 and dementia: Analyses of risk, disparity, and outcomes from electronic health records in the US

Alzheimer s & Dementia(2021)10.1002/alz.12296
Top 3%
6.7DataRank
Top 3%274 citations

Pamela B. Davis, Mark E. Gurney, Rong Xu, QuanQiu Wang

Discovery, Radiolabeling, and Evaluation of Subtype-Selective Inhibitors for Positron Emission Tomography Imaging of Brain Phosphodiesterase-4D

ACS Chemical Neuroscience(2020)10.1021/acschemneuro.0c00077
N/A
0DataRank · unranked
17 citations

Sanjay Telu, Rachel M. Dick, Masahiro Fujita, Maarten Ooms, Cheryl L. Morse +14 more

A Novel PDE4D Inhibitor BPN14770 Reverses Scopolamine-Induced Cognitive Deficits via cAMP/SIRT1/Akt/Bcl-2 Pathway

Frontiers in Cell and Developmental Biology(2020)10.3389/fcell.2020.599389
N/A
0DataRank · unranked
41 citations

Shichao Gao, Victor Zheng, Ling Chen, Min Ma, Shichen Shen +6 more

Effects of chronic inhibition of phosphodiesterase-4D on behavior and regional rates of cerebral protein synthesis in a mouse model of fragile X syndrome

Neurobiology of Disease(2021)10.1016/j.nbd.2021.105485
N/A
0DataRank · unranked
18 citations

Carrie Sheeler, Rachel Michelle Saré, Mark E. Gurney, Carolyn Beebe Smith, Michael Rosenheck

Association of COVID-19 with Risk and Progression of Alzheimer’s Disease: Non-Overlapping Two-Sample Mendelian Randomization Analysis of 2.6 Million Subjects

Journal of Alzheimer s Disease(2023)10.3233/jad-230632
N/A
0DataRank · unranked
7 citations

Mark E. Gurney, George Perry, Rong Xu, Pingjian Ding

Auditory N1 event-related potential amplitude is predictive of serum concentration of BPN14770 in fragile X syndrome

Molecular Autism(2024)10.1186/s13229-024-00626-0
N/A
0DataRank · unranked
6 citations

Elizabeth Berry‐Kravis, Mark Harnett, Scott A. Reines, Melody Reese, Abigail H. Outterson +5 more

Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer’s disease in patients with rheumatoid arthritis and psoriasis

PLoS ONE(2020)10.1371/journal.pone.0229819
N/A
0DataRank · unranked
153 citations

Rong Xu, David C. Kaelber, Mark E. Gurney, Mengshi Zhou

ROC Analysis of Biomarker Combinations in Fragile X Syndrome-Specific Clinical Trials: Evaluating Treatment Efficacy via Exploratory Biomarkers

Translational Psychiatry(2025)10.1038/s41398-025-03558-2
N/A
0DataRank · unranked
0 citations

Elizabeth Berry‐Kravis, Mark Harnett, Scott A. Reines, Melody R. Smith, Emma Auger +5 more